The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer

2003 ◽  
Vol 24 (1) ◽  
pp. 29-36 ◽  
Author(s):  
J. O. PRIOR ◽  
G. BARGHOUTH ◽  
J. F. DELALOYE ◽  
S. LEYVRAZ ◽  
A. BISCHOF DELALOYE
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Bone Metastases ◽  
Bone Scintigraphy ◽  
Primary Breast Cancer ◽  
Bone Marrow Scintigraphy

scholarly journals Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients

2021 ◽  
Author(s):  
Nils Martin Bruckmann ◽  
Julian Kirchner ◽  
Lale Umutlu ◽  
Wolfgang Peter Fendler ◽  
Robert Seifert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Bone Scintigraphy ◽  
Fdg Pet ◽  
Primary Breast Cancer ◽  
Whole Body ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Initial Staging

Abstract Objectives To compare the diagnostic performance of [18F]FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Material and methods A cohort of 154 therapy-naive patients with newly diagnosed, histopathologically proven breast cancer was enrolled in this study prospectively. All patients underwent a whole-body [18F]FDG PET/MRI, computed tomography (CT) scan, and a bone scintigraphy prior to therapy. All datasets were evaluated regarding the presence of bone metastases. McNemar χ2 test was performed to compare sensitivity and specificity between the modalities. Results Forty-one bone metastases were present in 7/154 patients (4.5%). Both [18F]FDG PET/MRI and MRI alone were able to detect all of the patients with histopathologically proven bone metastases (sensitivity 100%; specificity 100%) and did not miss any of the 41 malignant lesions (sensitivity 100%). CT detected 5/7 patients (sensitivity 71.4%; specificity 98.6%) and 23/41 lesions (sensitivity 56.1%). Bone scintigraphy detected only 2/7 patients (sensitivity 28.6%) and 15/41 lesions (sensitivity 36.6%). Furthermore, CT and scintigraphy led to false-positive findings of bone metastases in 2 patients and in 1 patient, respectively. The sensitivity of PET/MRI and MRI alone was significantly better compared with CT (p < 0.01, difference 43.9%) and bone scintigraphy (p < 0.01, difference 63.4%). Conclusion [18F]FDG PET/MRI and MRI are significantly better than CT or bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. Both CT and bone scintigraphy show a substantially limited sensitivity in detection of bone metastases. Key Points • [18F]FDG PET/MRI and MRI alone are significantly superior to CT and bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. • Radiation-free whole-body MRI might serve as modality of choice in detection of bone metastases in breast cancer patients.

scholarly journals Detection of Isolated Mammary Carcinoma Cells in Marrow of Patients with Primary Breast Cancer

1983 ◽  
Vol 76 (5) ◽  
pp. 359-364 ◽  
Author(s):  
D P Dearnaley ◽  
J P Sloane ◽  
S Imrie ◽  
R C Coombes ◽  
M G Ormerod ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Bone Metastases ◽  
Mammary Carcinoma ◽  
Primary Breast Cancer ◽  
Epithelial Membrane Antigen ◽  
Single Cells ◽  
Carcinoma Cells ◽  
Mammary Carcinoma Cells

Single cells from mammary carcinoma infiltrating bone marrow can be detected in marrow aspirates using immunocytochemical stains for epithelial membrane antigen (EMA). This technique has been used to examine marrow aspirates taken from multiple sites from 24 patients at surgery for breast cancer. Ten of these patients had EMA-positive cells in their marrow, while 32 marrow samples from patients who did not have carcinoma were negative. These results have been combined with those obtained by taking aspirates from single sites from 47 breast patients without known skeletal deposits. Follow up showed that the patients with EMA-positive cells in their marrow developed bone metastases at a significantly faster rate.

scholarly journals Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases.

BMJ ◽  
1987 ◽  
Vol 295 (6606) ◽  
pp. 1093-1096 ◽  
Author(s):  
J L Mansi ◽  
U Berger ◽  
D Easton ◽  
T McDonnell ◽  
W H Redding ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Bone Metastases ◽  
Primary Breast Cancer ◽  
Early Predictor

scholarly journals MRI and bone scintigraphy for breast cancer bone metastase: a meta-analysis

Open Medicine ◽  
2019 ◽  
Vol 14 (1) ◽  
pp. 317-323 ◽  
Author(s):  
Yue Rong ◽  
Hong Ren ◽  
Xianjun Ding
Keyword(s):  
Breast Cancer ◽  
Magnetic Resonance ◽  
Comparative Study ◽  
Bone Metastases ◽  
Bone Scintigraphy ◽  
Magnetic Resonance Image ◽  
Meta Analysis ◽  
Diagnostic Value ◽  
Satisfactory Method ◽  
The Comparative Study

AbstractObjectiveThe aim of this study was to compare the diagnostic value of magnetic resonance image (MRI) and bone scintigraphy (BS) in the diagnosis of breast cancer bone metastases.MethodsSearching in the databases including PubMed, Embase about the comparative study of MRI and bone scintigraphy in the diagnosis of breast cancer bone metastases during 2000~2018. After we screened further, the extracted effective data were calculated by Meta-Disc 1.4 software.ResultsWe obtained 4 articles. The pooled estimates for sensitivity of MRI, BS were 0.99 (95% CI, [0.95, 1.00]) and 0.93 (95% CI, [0.88, 0.97]) respectively; For specificity were 0.99 (95% CI, [0.95, 1.00]) and 0.86 (95% CI, [0.79, 0.92]) respectively. The AUC of SROC curve for MRI and BS were 0.9948 and 0.9675 respectively.ConclusionMRI remains to be a satisfactory method for the diagnosis of breast cancer bone metastases and should first be considered for patients.

Sign in / Sign up

Export Citation Format

Share Document